Last edited by Kekasa
Monday, August 10, 2020 | History

8 edition of Physiologically Based Pharmacokinetic Modeling found in the catalog.

Physiologically Based Pharmacokinetic Modeling

Science and Applications

by Micaela Reddy

  • 140 Want to read
  • 16 Currently reading

Published by Wiley-Interscience .
Written in English


The Physical Object
Number of Pages420
ID Numbers
Open LibraryOL7617885M
ISBN 100471478148
ISBN 109780471478140

This book is based on a three credit course in Basic Pharmacokinetics Chapters include: Introduction Background Mathematics Pharmacodynamic and Physiologically Based Pharmacokinetic Models Pharmaceutical Analysis Clinical Applications of Pharmacokinetics Content includes video tutorials, interactive graphs, calculators and tables.   Physiologically-based pharmacokinetic modeling to describe the pharmacokinetics of risperidone and 9-hydroxyrisperidone according to cytochrome P 2D6 phenotypes. Clin. Pharmacokinet. 59(1), 51–65 ().Crossref, Medline, CAS, Google Scholar; 9.

  The only book dedicated to physiologically-based pharmacokinetic modeling in pharmaceutical science. Physiologically-based pharmacokinetic (PBPK) modeling has become increasingly widespread within the pharmaceutical industry over the last decade, but without one dedicated book that provides the information researchers need to learn these new techniques, its 5/5(1).   Physiologically based pharmacokinetic modeling of lisinopril in children: a case story of angiotensin converting enzyme inhibitors. Lisinopril is an angiotensin converting enzyme inhibitor to treat hypertension.

A growing number of regulatory submissions include p hysiologically based pharmacokinetic (PBPK) models that require the use of specialised software platforms. While PBPK modelling is presently mentioned in several existing EMA guidelines, this is th e first to specifically provide detailed advice on. Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models Clin Pharmacol Ther. Dec;(6) doi: /cptCited by:


Share this book
You might also like
Place-names in Quebec. Place-names [in the] Thousand Islands. Place-names [in] Northern Canada

Place-names in Quebec. Place-names [in the] Thousand Islands. Place-names [in] Northern Canada

Intensive family therapy

Intensive family therapy

Managing food safety practices from farm to table

Managing food safety practices from farm to table

Treehouses, huts & forts-- even you can build

Treehouses, huts & forts-- even you can build

Janine and the field day finish

Janine and the field day finish

chemical industry.

chemical industry.

Hunting With The Fox Cubs

Hunting With The Fox Cubs

VD book

VD book

Sta synova tis fotias, odoipoviko sti kentriki Ameri ki

Sta synova tis fotias, odoipoviko sti kentriki Ameri ki

The green iguana manual

The green iguana manual

Urban growth and cultural change

Urban growth and cultural change

early inhabitants of the Americas.

early inhabitants of the Americas.

Other avenues

Other avenues

Classified subject index

Classified subject index

Wedding of the year

Wedding of the year

Namibian agriculture

Namibian agriculture

Labor union theories in America

Labor union theories in America

SunOS documentation tools.

SunOS documentation tools.

Physiologically Based Pharmacokinetic Modeling by Micaela Reddy Download PDF EPUB FB2

Physiologically-based pharmacokinetic (PBPK) modeling is becoming increasingly important in human health risk assessments and in supporting pharmacodynamic modeling for toxic responses. Organized by classes of compounds and modeling purposes so users can quickly access information, this is the first comprehensive reference of its by: Abstract.

Physiologically based pharmacokinetic (PBPK) modeling is a computational process that simulates the absorption, distribution, metabolism, and excretion of a substance in the body of an organism based on the interrelationships among key physiological, biochemical, and physicochemical factors using mathematical equations.

The only book dedicated to physiologically-based pharmacokinetic modeling in pharmaceutical science. Physiologically-based pharmacokinetic (PBPK) modeling has become increasingly widespread within the pharmaceutical industry over the last decade, but without one dedicated book that provides the information researchers need to learn these new techniques, its Cited by: A definitive, single source of information on PBPK modeling Physiologically-based pharmacokinetic (PBPK) modeling is becoming increasingly important in human health risk assessments and in supporting pharmacodynamic modeling for toxic responses.

Organized by classes of compounds and modeling purposes so users can quickly access information, this is the first comprehensive reference. Physiologically Based Pharmacokinetic (PBPK) Modeling: Methods and Applications in Toxicology and Risk Assessment presents foundational principles, advanced techniques and applications of PBPK modeling.

Contributions from experts in PBPK modeling cover topics such as pharmacokinetic principles, classical physiological models, the application of physiological models for dose.

Physiologically based pharmacokinetic (PBPK) models differ from classical PK models in that they include specific compartments for tissues involved in exposure, toxicity, biotransformation and clearance processes connected by blood flow (Figure 1).Compartments and blood flows are described using physiologically meaningful parameters, which allows for interspecies Cited by: 5.

Accounting for metabolism in a physiologically based pharmacokinetic (PBPK) model is important from a pharmacokinetics perspective. Hepatic and extrahepatic enzymatic biotransformations occur across species and are usually dependent upon age and perhaps sex.

Metabolism is either linked causally to toxicity or : Jeffrey W. Fisher, Jerry L. Campbell, Zhoumeng Lin. Fenebrutinib is a CYP3A substrate and time‐dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in logically‐based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug‐drug interactions (DDIs) and proposing doses for untested scenarios were developed.

The only book dedicated to physiologically-based pharmacokinetic modeling in pharmaceutical science Physiologically-based pharmacokinetic (PBPK) modeling has become increasingly widespread within the pharmaceutical industry over the last decade, but without one dedicated book that provides the information researchers need to learn these new techniques, its applications are seve.

However, only few pharmacokinetic studies of buprenorphine in children, particularly neonates, are available as conducting clinical trials in this population is especially challenging.

Physiologically-based pharmacokinetic (PBPK) modeling allows the prediction of drug exposure in pediatrics based on age-related physiological differences. Wang, N., Chen, L., Li, N. et al. Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.

Sci ( 14 PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF POPULATIONS Introduction Population Modeling with PBPK Healthy to Target Patient Population: Impact of Disease on Pharmacokinetics Modeling Subpopulations: Impact of Age, Gender, Co-morbidities, and Genetics on Pharmacokinetics   This chapter introduces the principles and development procedures for physiologically based pharmacokinetic (PBPK) models, and their application for nanoparticle toxicity studies.

PBPK models describe the concentration–time or mass–time profiles of chemicals or nanoparticles in individual tissues and organs within the body. Physiologically based pharmacokinetic (PBPK) models are increasingly used by drug developers to evaluate the effect of patient factors on drug exposure.

Between June and Decemberthe Office of Clinical Pharmacology at the US Food and Drug Administration (FDA) received 25 submissions containing PBPK analyses. The basic idea of physiological pharmacokinetics was to extend pharmacokinetic modeling so that quantitative aspects of other biological areas could be incorporated.

For example, this includes what is known about physiological differences and similarities among species, membrane bio-physics, biochemical kinetics, and others to be illustrated later. FDA’s Orange Book lists 17 currently marketed active pharmaceutical ingredients (API) formulated within ophthalmic suspensions in which a majority has 90% or more of the API undissolved.

We used an ocular physiologically based pharmacokinetic (O-PBPK) model to compare a suspension with a solution for ophthalmic products with dexamethasone (Dex) as the model drug. The pregnancy physiologically-based pharmacokinetic (p-PBPK) models developed for theoretical assessment of the kinetics of xenobiotics during pregnancy should take into account all the dynamic changes of the maternal and embryonic/foetal physiological functions.

The discussion of cardiac sensitization in Chapter 4 highlights the need to predict the blood concentration of an agent and the duration of exposure needed to achieve a critical blood concentration.

A tool that allows the investigation of those pharmacokinetic factors is the physiologically based pharmacokinetic (PBPK) model. Physiologically based pharmacokinetic model: distribution processes Christopher Ruark 7.

Metabolism and physiologically based pharmacokinetic models Jeffrey W. Fisher, Jerry L. Campbell Jr. and Zhoumeng Lin 8.

Physiologically based pharmacokinetic model: excretion via urine, feces, and breath Sami Haddad and Andy Nong 9. Physiologically based pharmacokinetic (PBPK) modeling in marine mammals is a challenge because of the lack of parameter information and the ban on exposure experiments.

To minimize uncertainty and variability, parameter estimation methods are required for the development of reliable PBPK models. The present study is the first to develop PBPK models for the lifetime bioaccumulation of p,p.

Considering that these drugs could share similar renal secretory pathways (e.g., via rOCT2 and rMATE1), a physiologically-based pharmacokinetic (PBPK) model incorporating semi-mechanistic kidney compartments was devised to predict drug-drug interactions (DDIs).Physiologically based pharmacokinetic modeling and simulation Peters et al physicoc hemical pr oper ties, pharma cologic al and safet y pro le s, and var ious DMPK parameter s of the le ad series.Objective: The aims of this study were to (1) determine whether opportunistically collected data can be used to develop physiologically based pharmacokinetic (PBPK) models in pediatric patients; and (2) characterize age-related maturational changes in drug disposition for the renally eliminated and hepatically metabolized antibiotic trimethoprim (TMP)-sulfamethoxazole (SMX).Cited by: 1.